U.S. markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.56+0.06 (+0.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close21.50
Open21.51
Bid21.02 x 800
Ask21.95 x 800
Day's Range20.91 - 21.60
52 Week Range13.88 - 83.57
Volume556,023
Avg. Volume1,105,465
Market Cap714.975M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-6.71
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.81
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
    GlobeNewswire

    Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

    NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. “Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pl

  • Intercept Appoints Andrew Saik as Chief Financial Officer
    GlobeNewswire

    Intercept Appoints Andrew Saik as Chief Financial Officer

    NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief Financial Officer. Mr. Saik brings more than 20 years of biopharma finance experience to his new role at Intercept. He was previously Chief Financial Officer of Vyne Therapeutics, where he led a buildout of

  • Intercept (ICPT) Moves 8% Higher: Will This Strength Last?
    Zacks

    Intercept (ICPT) Moves 8% Higher: Will This Strength Last?

    Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.